156 related articles for article (PubMed ID: 31540596)
1. SBRT for Localized Prostate Cancer: Is it Ready for Take-Off?
Mitin T; Henry A; Choudhury A; Chen RC; Pinkawa M; Spratt DE
Int J Radiat Oncol Biol Phys; 2019 Nov; 105(3):618-620. PubMed ID: 31540596
[No Abstract] [Full Text] [Related]
2. Extreme Hypofractionation with SBRT in Localized Prostate Cancer.
Gómez-Aparicio MA; Valero J; Caballero B; García R; Hernando-Requejo O; Montero Á; Gómez-Iturriaga A; Zilli T; Ost P; López-Campos F; Couñago F
Curr Oncol; 2021 Aug; 28(4):2933-2949. PubMed ID: 34436023
[TBL] [Abstract][Full Text] [Related]
3. Stereotactic body radiation therapy for prostate cancer-a review.
Haque W; Butler EB; Teh BS
Chin Clin Oncol; 2017 Sep; 6(Suppl 2):S10. PubMed ID: 28917248
[TBL] [Abstract][Full Text] [Related]
4. Energy use in moderate hypofractionation and stereotactic body radiotherapy for prostate cancer.
Laughlin BS; Anderson JD; Hobbis D; Armstrong M; Vargas CE; Rong Y; Yu NY
BJU Int; 2023 Dec; 132(6):648-650. PubMed ID: 37553875
[No Abstract] [Full Text] [Related]
5. Early Results of Extreme Hypofractionation Using Stereotactic Body Radiation Therapy for High-risk, Very High-risk and Node-positive Prostate Cancer.
Murthy V; Gupta M; Mulye G; Maulik S; Munshi M; Krishnatry R; Phurailatpam R; Mhatre R; Prakash G; Bakshi G
Clin Oncol (R Coll Radiol); 2018 Jul; 30(7):442-447. PubMed ID: 29571936
[TBL] [Abstract][Full Text] [Related]
6. How will the CHHiP trial affect the future of prostate radiotherapy?
Dearnaley D; Hall E
Expert Rev Anticancer Ther; 2018 Jul; 18(7):607-609. PubMed ID: 29774771
[No Abstract] [Full Text] [Related]
7. [Moderate or extreme hypofractionation and localized prostate cancer: The times are changing].
Line Krhili S; Créhange G; Albert-Dufrois H; Guimas V; Minsat M; Supiot S
Cancer Radiother; 2019 Oct; 23(6-7):503-509. PubMed ID: 31471253
[TBL] [Abstract][Full Text] [Related]
8. Are we ready to use hypofractionated instead of conventional radiotherapy for prostate cancer? Not yet.
Pellizzon ACA
Int Braz J Urol; 2019; 45(1):5-9. PubMed ID: 30860337
[No Abstract] [Full Text] [Related]
9. ONE SHOT - single shot radiotherapy for localized prostate cancer: study protocol of a single arm, multicenter phase I/II trial.
Zilli T; Scorsetti M; Zwahlen D; Franzese C; Förster R; Giaj-Levra N; Koutsouvelis N; Bertaut A; Zimmermann M; D'Agostino GR; Alongi F; Guckenberger M; Miralbell R
Radiat Oncol; 2018 Sep; 13(1):166. PubMed ID: 30180867
[TBL] [Abstract][Full Text] [Related]
10. PROshot: Internal Mammary Coverage, Dose-Reduced Radiation After Transoral Surgery, Sequencing of Total Neoadjuvant Therapy for Rectal Cancer, Hypofractionated Whole Breast Intensity Modulated Radiation Therapy, Hypofractionated Prostate Fossa Radiation Therapy, and Stereotactic Body Radiation Therapy for Oligoprogressive Cancer.
Dulaney C; Dover L
Pract Radiat Oncol; 2022; 12(2):79-83. PubMed ID: 35248240
[No Abstract] [Full Text] [Related]
11. [Hypofractionated radiotherapy in prostate cancer].
Supiot S; Créhange G; Latorzeff I; Pommier P; Paumier A; Rio E; Delaroche G; Guérif S; Catton C; Martin J; Lisbona A
Cancer Radiother; 2013 Oct; 17(5-6):349-54. PubMed ID: 23973460
[TBL] [Abstract][Full Text] [Related]
12. Long-term outcome of a moderately hypofractionated, intensity-modulated radiotherapy approach using an endorectal balloon for patients with localized prostate cancer.
Teh BS; Lewis GD; Mai W; Pino R; Ishiyama H; Butler EB
Cancer Commun (Lond); 2018 Apr; 38(1):11. PubMed ID: 29764515
[TBL] [Abstract][Full Text] [Related]
13. Moderate hypofractionation and stereotactic body radiation therapy in the treatment of prostate cancer.
Beckta JM; Nosrati JD; Yu JB
Urol Oncol; 2019 Sep; 37(9):619-627. PubMed ID: 30738746
[TBL] [Abstract][Full Text] [Related]
14. Comparing photon and proton-based hypofractioned SBRT for prostate cancer accounting for robustness and realistic treatment deliverability.
Goddard LC; Brodin NP; Bodner WR; Garg MK; Tomé WA
Br J Radiol; 2018 May; 91(1085):20180010. PubMed ID: 29436852
[TBL] [Abstract][Full Text] [Related]
15. Will SBRT replace conventional radiotherapy in patients with low-intermediate risk prostate cancer? A review.
Arcangeli S; Scorsetti M; Alongi F
Crit Rev Oncol Hematol; 2012 Oct; 84(1):101-8. PubMed ID: 22257653
[TBL] [Abstract][Full Text] [Related]
16. Are We Now Able to Define Guidelines for Moderate Hypofractionation in Prostate Cancer Radiation Therapy?
Brenner DJ; Hall EJ
Int J Radiat Oncol Biol Phys; 2018 Mar; 100(4):871-873. PubMed ID: 29485065
[No Abstract] [Full Text] [Related]
17. Breast, Prostate, and Rectal Cancer: Should 5-5-5 Be a New Standard of Care?
Ling DC; Vargo JA; Beriwal S
Int J Radiat Oncol Biol Phys; 2020 Oct; 108(2):390-393. PubMed ID: 32890517
[No Abstract] [Full Text] [Related]
18. Hypofractionated radiotherapy recommendations for localized prostate cancer in Brasil.
Palhares DMF; Pimentel LCF; Castilho MS; Costa ABD; Reisner ML; Kuhnen FQ; Pássaro A; Leite ETT; Faustino FLC; Obst FM; Costa FNBBF; Pioner GT; Carvalho ÍT; Silva JLFD; Morikawa LKK; Zanuncio PHDR; Hanriot RM; Rosa AA
Rev Assoc Med Bras (1992); 2021 Jan; 67(1):7-18. PubMed ID: 34161478
[TBL] [Abstract][Full Text] [Related]
19. A pilot study of intensity modulated radiation therapy with hypofractionated stereotactic body radiation therapy (SBRT) boost in the treatment of intermediate- to high-risk prostate cancer.
Oermann EK; Slack RS; Hanscom HN; Lei S; Suy S; Park HU; Kim JS; Sherer BA; Collins BT; Satinsky AN; Harter KW; Batipps GP; Constantinople NL; Dejter SW; Maxted WC; Regan JB; Pahira JJ; McGeagh KG; Jha RC; Dawson NA; Dritschilo A; Lynch JH; Collins SP
Technol Cancer Res Treat; 2010 Oct; 9(5):453-62. PubMed ID: 20815416
[TBL] [Abstract][Full Text] [Related]
20. Patient-reported quality of life after stereotactic body radiation therapy versus moderate hypofractionation for clinically localized prostate cancer.
Johnson SB; Soulos PR; Shafman TD; Mantz CA; Dosoretz AP; Ross R; Finkelstein SE; Collins SP; Suy S; Brower JV; Ritter MA; King CR; Kupelian PA; Horwitz EM; Pollack A; Abramowitz MC; Hallman MA; Faria S; Gross CP; Yu JB
Radiother Oncol; 2016 Nov; 121(2):294-298. PubMed ID: 27890426
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
